Um estudo de extensão para aprender sobre a segurança a longo prazo do Fazirsiran e se o Fazirsiran pode ajudar pessoas com doença hepática alfa-1 antitripsina
Um estudo de extensão aberto de fase 3 para avaliar a segurança e a eficácia a longo prazo do Fazirsiran em participantes com doença hepática associada à deficiência de alfa-1 antitripsina
The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver.
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292], AROAAT2002 [NCT03946449] , TAK-999-3001 [NCT05677971], or TAK-999-3002 [NCT06165341]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Alemanha, 52074
- Universitätsklinikum der RWTH Aachen
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92037-1337
- UCSD Altman Clinical and Translational Research Institute
-
Redwood City, California, Estados Unidos, 94063
- Stanford Medicine Outpatient Center
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610-3010
- UF Clinical and Translational Science Institute
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242-1009
- University Of Iowa Hospitals And Clinics
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425-8900
- Medical University of South Carolina - Hollings Cancer Center - PPDS
-
-
-
-
-
Funchal, Portugal, 9000-168
- Hospital Nélio Mendonça
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Addenbrooke's Hospital
-
Edinburgh, Reino Unido, EH16 4SA
- Royal Infirmary of Edinburgh - PPDS
-
-
-
-
-
Vienna, Áustria, A-1090
- Medizinische Universitat Wien (Medical University of Vienna)
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants must meet all of the following criteria to be eligible for inclusion in the study:
- The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
- The participant is able to read, understand, and complete the study questionnaires electronically per investigator's judgment.
- The participant has provided informed consent (ICF) (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any study procedures.
Note: For participants who comprehend, can provide informed consent, and are unable to sign the ICF, an impartial witness may sign the ICF on behalf of the participant after the participant has orally consented to the participant's participation in the study.
-
The participant enrolling in this open-label extension (OLE) study will have participated in a previously qualifying study, and will be considered for eligibility based on the following study-specific criteria:
-
AROAAT2001:
- Participants with fibrosis may roll over into this OLE study after they reach their next regularly scheduled, Q12W visit.
- Participants with fibrosis who have completed the AROAAT2001 study may be enrolled into the OLE study.
-
AROAAT2002:
- Participants in Cohorts 1 and 1b may roll over after completing the 24-week primary study period.
- Participants in Cohort 2 may roll over after completing the 48-week primary study period.
- Participants who have completed the study may be enrolled into the OLE study.
-
TAK-999-3001 and TAK-999-3002:
- Participants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
-
The participant is a nonsmoker (defined as: does not smoke cigarettes daily for at least 24 weeks) with current nonsmoking status confirmed by urine cotinine at Day 1.
- E-cigarettes (vapor) are not permitted.
- The participant may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the investigator.
-
The participant must have suitable venous access for blood sampling.
-
It must be confirmed that the participant does not have hepatocellular carcinoma (HCC). Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) imaging to exclude HCC before enrollment.
- AFP >20 nanogram per milliliter (ng/mL).
- AFP 15 to 19 ng/mL at enrollment if that is >2 times prestudy levels (if available).
- Any liver lesion >10 millimeter (mm) (longest diameter) detected by ultrasound.
- Poor visibility of liver on ultrasound.
-
A person of childbearing potential (POCBP) must have a negative urine pregnancy test performed within 3 days prior to Day 1 dosing in this study (sensitive to 25 International Unit [IU] human chorionic gonadotropin [hCG]).
-
The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study. Participants who terminate early must use appropriate contraception methods for 6 months after the last dose of study intervention. Male participants who terminate early must not donate sperm for at least 6 months after the last dose of study intervention.
-
Sexual abstinence, for the purposes of this study, is only considered a highly effective method of contraception when considered to align with the preferred and usual lifestyle of the participant. It will be employed for the entire duration of the study and the 6 months after last dose of study intervention.
-
Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.
Exclusion Criteria:
- The participant will be excluded from the study if any of the following exclusion criteria are met:
- The participant is likely to require major surgery. Major surgery typically requires at least 1 night in the hospital. Examples include laparoscopic surgery (except cholecystectomy and tubal ligation); Gastrointestinal tract (GI) tract surgery including 1 or more segments of the colon or terminal ileum; open resection of organs; large joint replacements; mastectomy with reconstruction; and spine, thoracic, vascular, or intracranial surgery.
- The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.
- The participant has abnormal finding(s) of clinical relevance during the evaluation before the first study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results. For US only: Participants with baseline emphysema may be allowed into the OLE if their lung disease has been stable.
- The participant had significant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002 that would affect the conduct of this study.
- The participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002.
- Female participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
- The participant has a Child-Turcotte-Pugh (CTP) score >=7 OR (Model for End-Stage Liver Disease) MELD score >14.
- The participant meets Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatinine criteria as per the protocol. All laboratory tests used as exclusion criteria may be repeated once and the repeat value may be used for study eligibility determination.
- Participants who have a newly-diagnosed malignancy or recurrence of malignancy (except for resected cutaneous basal cell carcinoma, squamous cell carcinoma, superficial bladder tumors, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- The participant is experiencing a pulmonary exacerbation at the time of enrollment (participant enrollment may be temporarily delayed after the clinical resolution of an exacerbation).
- The participant has unstable, poorly controlled, or severe hypertension. Participants may be reevaluated once their blood pressure is successfully controlled.
- The participant has a history of more than moderate alcohol consumption within 12 months before the Day 1 visit.
- The participant has a history of hypersensitivity or allergies to fazirsiran or any associated excipients.
- The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk.
- The participant has a history of clinically significant hematologic, renal, hepatic, cardiovascular, infectious, pulmonary, neurologic, psychiatric, GI, systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
- The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
- The participant is unable to return for all scheduled study visits.
- Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
- The participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
- The participant who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- The participant who participates in other studies involving an investigational product.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Fazirsiran 200 mg
Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292), AROAAT2002 (NCT03946449), TAK-999-3001 [NCT05677971] and TAK-999-3002 (NCT06165341) will rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter until fazirsiran receives approval and is commercially available in the participant's country, until a participant withdraws from the study or the sponsor decides to terminate the study. |
Fazirsiran will be injected subcutaneously.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Prazo: From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported. |
From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
|
|
Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function Parameters
Prazo: Baseline (current study), up to EOS (current study up to 10 years])
|
Standard pulmonary function parameters measured will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion. |
Baseline (current study), up to EOS (current study up to 10 years])
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
Prazo: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
Vital signs include body temperature, respiratory rate, sitting blood pressure (systolic and diastolic, resting more than 5 minutes), pulse, oxygen saturation. Clinical significance of vital signs will be determined at the investigator's discretion. |
From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
|
Number of Participants With Clinically Significant Changes in Laboratory Parameters
Prazo: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
Laboratory parameters include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion. |
From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
Prazo: At Week 102 (current study)
|
Number of participants from Studies AROAAT2001 and AROAAT2002 with no progression from baseline of at least 1 stage of histologic fibrosis (by Meta-Analysis of Histological Data in Viral Hepatitis [METAVIR] staging) on liver biopsy at Week 102 will be reported. |
At Week 102 (current study)
|
|
Number of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
Prazo: At Week 102 (current study)
|
Number of participants from Studies AROAAT2001 and AROAAT2002 with baseline fibrosis of F1 or higher, a decrease from baseline of at least 1 stage of histologic fibrosis (by METAVIR staging) on liver biopsy at Week 102 will be reported. |
At Week 102 (current study)
|
|
Change from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102
Prazo: Baseline (current study), Week 102 (current study)
|
Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. |
Baseline (current study), Week 102 (current study)
|
|
Change from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy
Prazo: Baseline (current study), Week 102 (current study)
|
Change in portal inflammation score in liver biopsy, based on pathology slide reads for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. |
Baseline (current study), Week 102 (current study)
|
|
Change from Baseline in Liver Stiffness Assessed by Magnetic Resonance Elastography (MRE)
Prazo: Baseline (current study), up to EOS (current study up to 10 years])
|
Change from baseline in MRE-derived liver stiffness will be assessed. |
Baseline (current study), up to EOS (current study up to 10 years])
|
|
Change from Baseline in Liver Stiffness Assessed by Vibration-Controlled Transient Elastography (VCTE)
Prazo: Baseline (current study), up to EOS (current study up to 10 years])
|
Change from baseline in VCTE-derived liver stiffness will be assessed. |
Baseline (current study), up to EOS (current study up to 10 years])
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Study Director, Takeda
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças Genéticas, Congênitas
- Doenças Respiratórias
- Doenças do aparelho digestivo
- Doenças pulmonares
- Doenças do Fígado
- Enfisema subcutâneo
- Enfisema
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Deficiência de alfa 1-antitripsina
Outros números de identificação do estudo
Outros números de identificação do estudo
- TAK-999-3003
- 2023-503497-21-00 (Ctis: EU CTIS)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Critérios de acesso de compartilhamento IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .